Tyrosine-protein kinase ABL1 also known as ABL1 is a protein that, in humans, is encoded by the ABL1 gene (previous symbol ABL) located on chromosome 9. c-Abl is sometimes used to refer to the version of the gene found within the mammalian genome, while v-Abl refers to the viral gene, which was initially isolated from the Abelson murine leukemia virus.
Structure The ABL1 protein is a non-receptor tyrosine kinase that contains both Src homology 3 (SH3) and Src homology 2 (SH2) domains, followed by a tyrosine kinase domain. These domains are involved in regulating its activity and interactions with other proteins. ABL1 also contains signals that allow it to shuttle between the nucleus and cytoplasm, as well as regions that enable binding to the actin cytoskeleton.
Function The ABL1 proto-oncogene encodes a cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response such as DNA repair. Activity of ABL1 protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for ABL1. A characteristic translocation, t(9;22), results in the head-to-tail fusion of the BCR and ABL1 genes, leading to a fusion gene present in many cases of chronic myelogenous leukemia. The ABL1 gene is expressed as either a 6- or a 7-kb mRNA transcript, with alternatively spliced first exons spliced to the common exons 2–11.
Clinical significance
This gene is a partner in a fusion gene with the BCR gene in the Philadelphia chromosome, a characteristic abnormality in chronic myelogenous leukemia (CML) and rarely in some other leukemia forms. In CML, the gene is activated by being translocated within the BCR (breakpoint cluster region) gene on chromosome 22. This new fusion gene, BCR-ABL, encodes an unregulated, cytoplasm-targeted tyrosine kinase that allows the cells to proliferate without being regulated by cytokines. This, in turn, allows the cell to become cancerous. The resulting BCR-ABL1 fusion protein exhibits constitutive tyrosine kinase activity and activates multiple downstream signaling pathways, including RAS/MAPK, PI3K/AKT, and Src family kinases, which promote uncontrolled cell proliferation and survival. This can also lead to a clonal myeloproliferative disorder. The BCR-ABL protein can be inhibited by various small molecules. One such inhibitor is imatinib mesylate, which occupies the tyrosine kinase domain and inhibits BCR-ABL's influence on the cell cycle. Second generation BCR-ABL tyrosine-kinase inhibitors are also under development to inhibit BCR-ABL mutants resistant to imatinib.
Interactions ABL gene has been shown to interact with:
Regulation There is some evidence that the expression of Abl is regulated by the microRNA miR-203.
See also BCR gene
References
Further reading
External links Genes,+abl at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Online Mendelian Inheritance in Man (OMIM): 189980 (ABL) Abelson+Leukemia+Virus at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Drosophila Abl tyrosine kinase - The Interactive Fly ABL1 Info with links in the Cell Migration Gateway ABL1 on the Atlas of Genetics and Oncology Human ABL1 genome location and ABL1 gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: P00519 (Human Tyrosine-protein kinase ABL1) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: P00520 (Mouse Tyrosine-protein kinase ABL1) at the PDBe-KB.






